TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Update

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 83,800 shares, a growth of 45.5% from the December 15th total of 57,600 shares. Approximately 2.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 37,300 shares, the days-to-cover ratio is presently 2.2 days.

Insider Buying and Selling at TriSalus Life Sciences

In other TriSalus Life Sciences news, major shareholder Equity Ab Frankenius acquired 62,972 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The stock was bought at an average price of $3.97 per share, with a total value of $249,998.84. Following the completion of the purchase, the insider now owns 6,230,748 shares of the company’s stock, valued at approximately $24,736,069.56. This represents a 1.02 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders purchased 70,012 shares of company stock valued at $281,235 in the last quarter. 32.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Walleye Capital LLC purchased a new position in TriSalus Life Sciences in the 3rd quarter worth approximately $66,000. Virtu Financial LLC bought a new position in shares of TriSalus Life Sciences in the third quarter worth approximately $92,000. Vestcor Inc bought a new position in shares of TriSalus Life Sciences in the third quarter worth approximately $108,000. MSD Partners L.P. purchased a new position in shares of TriSalus Life Sciences in the third quarter worth $184,000. Finally, Geode Capital Management LLC raised its holdings in TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after buying an additional 62,542 shares during the last quarter. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Stock Performance

NASDAQ:TLSI traded down $0.00 during trading hours on Thursday, reaching $4.80. The company’s stock had a trading volume of 10,689 shares, compared to its average volume of 20,829. The firm has a 50-day simple moving average of $4.39 and a 200-day simple moving average of $4.78. TriSalus Life Sciences has a 1 year low of $3.50 and a 1 year high of $10.42. The firm has a market capitalization of $146.26 million, a price-to-earnings ratio of -1.93 and a beta of 0.51.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on TLSI. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They set an “outperform” rating and a $12.50 target price for the company. Roth Mkm initiated coverage on shares of TriSalus Life Sciences in a report on Monday, November 11th. They issued a “buy” rating and a $11.00 price target on the stock. Canaccord Genuity Group dropped their price objective on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 15th. Finally, Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $11.79.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.